Compare PRSO & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRSO | TCRT |
|---|---|---|
| Founded | 2008 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.8M | 8.1M |
| IPO Year | 2001 | N/A |
| Metric | PRSO | TCRT |
|---|---|---|
| Price | $0.96 | $4.24 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 262.9K | 65.9K |
| Earning Date | 11-10-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $13,001,000.00 | $6,000.00 |
| Revenue This Year | N/A | $5,680,500.00 |
| Revenue Next Year | $23.70 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2.15 | N/A |
| 52 Week Low | $0.52 | $1.31 |
| 52 Week High | $2.37 | $6.20 |
| Indicator | PRSO | TCRT |
|---|---|---|
| Relative Strength Index (RSI) | 46.23 | 69.91 |
| Support Level | $0.97 | $4.10 |
| Resistance Level | $1.15 | $4.50 |
| Average True Range (ATR) | 0.08 | 0.35 |
| MACD | 0.03 | 0.08 |
| Stochastic Oscillator | 46.77 | 88.44 |
Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz, to 300 GHz. Geographically the company generates revenue from the United States, Hong Kong, Taiwan, and the Rest of the World.
Alaunos Therapeutics Inc is a preclinical stage obesity and metabolic health drug development company that is aiming to develop a small molecule-based drug to treat obesity and other metabolic disorders that have a differentiated profile relative to currently marketed and in development oral and injectable products. The company focuses on evaluating the impact of ALN1001, its primary program, and its derivatives on lipid deposition and gene expression. It aims to develop an oral obesity compound that addresses many of the shortcomings of injectable GLP-1 receptor agonists including preserving lean muscle mass.